Ventyx Biosciences

NLRP3 protein inhibitors show promise in treating autoimmune, inflammatory, neurodegenerative, and metabolic diseases. Over 20 pharma companies are developing 25+ inhibitors, with notable progress in clinical trials by Halia Therapeutics, Ventus Therapeutics, and Novo Nordisk.

Sanofi reports 15.7% Q3 sales growth, driven by vaccine sales and strong business performance, raising 2024 EPS guidance. Dupixent sales up 23.8%, with full-year target confirmed at €13 billion. Pharma launches grew 67.1%, led by ALTUVIIIO, Nexviazyme, and Rezurock. Vaccines sales increased 25.5%, boosted by flu sales and Beyfortus. Opella sales rose 7.9%, supported by Qunol acquisition. R&D expenses grew 12.7%, while SG&A expenses grew 6.4%. Business EPS at €2.86, up 12.2% reported and 17.6% at CER. Four regulatory approvals and four positive phase 3 data readouts achieved. Negotiations underway to transfer a controlling stake of Opella to CD&R. 2024 business EPS guidance upgraded to low single-digit growth at CER.

Tulisokibart maintained clinical and endoscopic improvements in IBD patients through week 50 in phase II trial extensions, with 48% of ulcerative colitis patients and 56% of Crohn's disease patients achieving clinical remission. The drug was well-tolerated with no identified safety signals.

Ventyx Biosciences presented 52-week LTE data on tamuzimod for ulcerative colitis at UEG Week, reinforcing its potential as a best-in-class oral therapy.

Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to the ARTEMIS-UC trial. The study incorporated a predictive biomarker for response, showing significant clinical remission, endoscopic improvement, and clinical response in patients on tulisokibart compared to placebo. A phase 3 program is planned to confirm these results.

The article discusses the importance of SSR (Server-Side Rendering) in modern web development, emphasizing its role in enhancing performance and user experience.

Ventyx Biosciences initiates Phase 2a trial of VTX3232, an oral NLRP3 inhibitor, in early Parkinson’s disease patients, aiming to assess safety, tolerability, and biomarkers. Topline results expected in 2025.

Expert in IP strategy for FDA-approved drugs and clinical trials, with significant M&A experience in pharma. Represented numerous companies and investors in financings, IPOs, and IP diligence. Co-creator of healthcare investment initiatives and board member at LaunchBio.

Christopher Ma, Brian Feagan, Vipul Jairath, Reena Khanna, Parambir S. Dulai, and William J Sandborn disclose various financial relationships with pharmaceutical companies and research organizations, including grants, personal fees, and other forms of compensation, outside their submitted work. Robert Battat and Parambir S. Dulai report no conflict of interest.